Tag: Cancer: Stomach
FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer
Vyloy is the first and only CLDN18.2-targeted therapy approved in the United States
Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer
However, omission does result in reductions in neutropenia, thrombocytopenia, and use of granulocyte colony-stimulating factor
Blood Test Results Can Enhance Assessment of Cancer Risk
Blood test results enhance assessment of risk for patients presenting with nonspecific abdominal symptoms
Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants
Lifetime cumulative risk for advanced gastric cancer 10.3 and 6.5 percent for male and female carriers, respectively
Gastrectomy for Gastric Cancer Tied to Lower Risk for Cardiovascular Events
Risk for cardiovascular diseases similar between gastric cancer patients who undergo endoscopic resection and the general population
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
Improved overall survival, progression-free survival seen, including among patients with low PD-L1 expression
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
Improvement seen in progression-free survival among patients who had disease progression on first-line chemotherapy
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
Increased body fat only explained a small proportion of the association
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
Improvement seen in progression-free survival with add-on pembrolizumab in gastroesophageal junction adenocarcinoma
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
Screening tool was well calibrated and had better discrimination than previous models including HUNT, Kunzmann
